Teva Pharmaceutical Industries (TEVA) to Release Quarterly Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is expected to announce its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of $0.52 per share and revenue of $3.8457 billion for the quarter. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:00 AM ET.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.71 EPS. On average, analysts expect Teva Pharmaceutical Industries to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $30.66 on Monday. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $35.25 billion, a PE ratio of 25.55, a P/E/G ratio of 2.70 and a beta of 0.76. Teva Pharmaceutical Industries has a 12-month low of $14.52 and a 12-month high of $37.35. The business’s fifty day moving average price is $31.22 and its 200 day moving average price is $29.08.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on TEVA shares. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Piper Sandler reissued an “overweight” rating and set a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Truist Financial boosted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Finally, Bank of America boosted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.78.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Brian Savage sold 1,127 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $35,692.09. Following the completion of the sale, the insider directly owned 10,914 shares of the company’s stock, valued at $345,646.38. This represents a 9.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Richard Daniell sold 17,295 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the sale, the executive vice president directly owned 85,755 shares of the company’s stock, valued at approximately $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 920,901 shares of company stock worth $30,056,789. Insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd raised its stake in Teva Pharmaceutical Industries by 567.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after acquiring an additional 1,134 shares during the last quarter. Global Retirement Partners LLC raised its stake in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after acquiring an additional 292 shares during the last quarter. Advocate Investing Services LLC purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $53,000. Finally, DV Equities LLC purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $69,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.